The iNDxer, their portable core technology, counts nucleic acid biomarkers in minimally processed samples to determine the number of pathogenic bacteria present. The test targets RNA markers specific to harmful microbes, providing comprehensive details on the infection in just 30 minutes. This enables physicians to prescribe the ideal antibiotic needed for a particular patient, reducing healthcare costs and fighting the spread of antibiotic resistance. Nanopore Diagnostics was founded in 2012 by Tom Cohen and is based in the United States.